Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Receivables (2016 - 2025)

Adma Biologics' Change in Receivables history spans 13 years, with the latest figure at $20.8 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 14820.57% year-over-year to $20.8 million; the TTM value through Dec 2025 reached $108.4 million, up 380.25%, while the annual FY2025 figure was $108.4 million, 380.25% up from the prior year.
  • Change in Receivables reached $20.8 million in Q4 2025 per ADMA's latest filing, down from $27.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $49.4 million in Q1 2025 to a low of -$19.5 million in Q2 2024.
  • Average Change in Receivables over 5 years is $7.3 million, with a median of $5.2 million recorded in 2021.
  • Peak YoY movement for Change in Receivables: crashed 1654.71% in 2021, then surged 14820.57% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $8.2 million in 2021, then tumbled by 165.95% to -$5.4 million in 2022, then grew by 27.78% to -$3.9 million in 2023, then surged by 96.38% to -$141000.0 in 2024, then soared by 14820.57% to $20.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Change in Receivables are $20.8 million (Q4 2025), $27.9 million (Q3 2025), and $10.3 million (Q2 2025).